{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-26-000058","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-08-04T21:20:45+00:00","discovered_at":"2026-08-04T21:22:00.674577+00:00","generated_at":"2026-08-04T21:22:14.269728+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cumberland closes $100M Apotex deal, pays $1.50 special dividend, reports Q2 loss","bullets":["Closed $100M strategic transaction with Apotex Health; received $111M total including inventory and transition services.","Paid special cash dividend of $1.50 per share on July 31, 2026 to shareholders of record July 23.","Q2 2026 loss from continuing operations $3.1M; net loss $4.1M; cash $4M; retired $5.2M credit line.","Phase 2 ifetroban in DMD showed biomarker evidence of cardiac protection; cancer metastasis study met safety endpoint.","Metastatic recurrence 17% ifetroban vs 50% placebo (p=0.09); deaths from metastasis 0% vs 30% (p=0.037)."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-26-000058","json":"https://secwatch.observer/filing/0001087294-26-000058.json","markdown":"https://secwatch.observer/filing/0001087294-26-000058.md","text":"https://secwatch.observer/filing/0001087294-26-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/0001087294-26-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/cpix-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T21:22:14.269728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}